Akiram Therapeutics to present promising data on the therapeutic potential of its drug candidate at EANM Congress
Akiram Therapeutics, a Swedish biotech company specializing in radiotherapy will present promising preclinical data at the European Association of Nuclear Medicine (EANM) Congress taking place in Vienna, Austria on September 9–13. The data showcases the potential of the company’s radiopharmaceutical 177Lu-AKIR001 targeting tumor lesions for therapeutic purposes. A Phase 1 study is planned for 2024.
Akiram Therapeutics has developed a new type of targeted radioimmunotherapy, 177Lu-AKIR001. The therapy has shown promising results in several preclinical studies and holds the potential to become a first-in-class treatment. 177Lu-AKIR001 targets multiple cancer types, including anaplastic and iodine-refractory thyroid cancer, head and neck squamous cell carcinoma and non-small cell lung cancer.
At the upcoming EANM Congress, Akiram will present findings from preclinical development work showcasing the utility of the radiotracer drug candidate, 177Lu-AKIR001, for therapeutic targeting of tumor lesions in a preclinical model of anaplastic thyroid cancer (ATC). The study aims to investigate the safety of 177Lu-AKIR001 in several species as well as the efficacy of the drug in preclinical models of ATC.
The results will be presented by Dr. Anja Mortensen, co-founder and CTO.
Time and venue: September 10 at 5.01 p.m. in Hall G2, Session number 609.
"We are honored to have the opportunity to present at the Annual EANM Congress. We look forward to sharing promising data about our drug candidate, which we believe holds the potential to significantly impact patient care and radiopharmaceutical sciences in the future. Participating in this global conversation that's shaping the future of Nuclear Medicine is genuinely exciting,” says Dr. Anja Mortenson, co-founder and CTO at Akiram.
The European Association of Nuclear Medicine (EANM)
Celebrating its 36th year, the upcoming Annual Congress of the European Association of Nuclear Medicine (EANM) stands as the eminent global gathering, drawing industry leaders from around the world to engage in discussions surrounding the forefront of advancements and trends in the dynamic field of Nuclear Medicine. Read more.
About Akiram’s drug candidate
177Lu-AKIR001 was developed using antibody phage display selections followed by affinity maturation towards the cancer marker CD44v6 and is combined with the radiation component lutetium (177Lu). Results from preclinical studies support the validity of 177Lu-AKIR001 as a promising, novel antibody-based radiopharmaceutical targeting cancers with high expression of CD44v6 including ATC.
For more information, please contact:
Marika Nestor, CEO
Email: marika.nestor@akiramtherapeutics.com
Phone: +46 702 34 18 81
About Akiram Therapeutics
Akiram Therapeutics is a Swedish biotech company focused on the development of targeted radioimmunotherapy for cancer, which is based on a proprietary antibody targeting the cancer marker CD44v6 combined with a radiation component. The therapy has generated strong preclinical results in cancer models in conditions that currently lack effective treatments. With the potential for its drug candidate to be classified as an orphan drug and recognized as first-in-class, the company is dedicated to advancing research in this field, including indications in head and neck cancer, AML (Acute Myeloid Leukemia), lung cancer, and aggressive thyroid cancer. Headquartered in Uppsala, Sweden, Akiram Therapeutics is staffed with experts in radiation science research, cancer precision medicine, and drug development. To learn more, please visit Akiram’s website and follow Akiram on LinkedIn.
